---
title: "DFX Corp Acquires Biomaterials Leader MycoWorks"
date: 2026-02-10
draft: false
summary: "DFX Corp has acquired MycoWorks, the pioneer behind Fine Mycelium technology, to accelerate the global scaling of high-performance bio-based materials."
tags: ["MycoWorks", "DFX Corp", "Mycelium", "Fine Mycelium", "Reishi"]
category: "M&A"
company: ["DFX Corp", "MycoWorks"]
company_type: ["Bioplastic Producer", "Technology Company"]
source: "World Bio Market Insights"
---

DFX Corp has officially announced the acquisition of MycoWorks, a biotechnology company renowned for its proprietary Fine Mycelium™ platform. This strategic move, finalized on February 10, 2026, marks a significant consolidation point in the alternative materials sector, signaling a shift from venture-backed innovation to industrial-scale implementation.

## Scaling Bio-Fabrication

The acquisition by DFX Corp aims to leverage MycoWorks' established technical supremacy in mycelium cultivation to meet the growing demand for luxury leather alternatives. While financial terms were not disclosed, industry analysts suggest the deal is structured to fund the immediate expansion of MycoWorks’ production facilities.

MycoWorks gained prominence with the launch of Reishi™, a material that mimics the performance and hand-feel of premium animal leather without the plastic coatings often found in early-generation vegan leathers. By joining the DFX Corp portfolio, MycoWorks gains access to robust global supply chains and manufacturing infrastructure necessary to transition Reishi™ from boutique collections to mass-market automotive and fashion applications.

## Advancing Fine Mycelium Technology

Unlike standard mushroom leathers, which often compress mycelium foam into a mat, MycoWorks employs a patented process called Fine Mycelium. This technology engineers mycelium cells to interlock as they grow, creating a densely woven, high-strength cellular structure. The result is a biomaterial that matches the durability of cowhide while significantly reducing greenhouse gas emissions and water usage.

"This acquisition represents the maturation of the bio-fabrication industry," stated a DFX Corp spokesperson. "MycoWorks has solved the quality equation; DFX is here to solve the volume equation."

## Market Consolidation in 2026

The deal reflects a broader trend in 2026, where specialized biotechnology firms are merging with larger industrial conglomerates to overcome the "valley of death" between pilot production and commercial viability. As regulatory pressure on synthetic, petrochemical-based textiles increases, the integration of scalable, bio-based solutions like Reishi™ has become a critical competitive advantage for material holding companies.

**Source:** [Read more](https://www.mycostories.com/post/mycoworks-acquired-by-investment-firm-as-mycelium-materials-sector-consolidates)